GlassScriptPhysician profile
Peter C Debelius-Enemark
NPI 1376593913
$1,734.88
in general payments reported to CMS, 2019-2025
19 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.66 · 2020: $21.89 · 2021: $19.04 · 2024: $610 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $315.80 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $228.33 | 2024-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.64 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $143.18 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $132.31 | 2024-2025 | Fanapt |
| Lundbeck LLC | $97.46 | 2025 | Rexulti |
| Abbvie INC. | $85.72 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $79.96 | 2025 | |
| Axsome Therapeutics, INC. | $71.50 | 2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $63.11 | 2025 | Austedo Xr |
| Bausch Health US, LLC | $56.45 | 2024-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $53.09 | 2024-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $43.55 | 2019-2020 | |
| Tempus Ai, INC | $40.73 | 2024 | |
| Almatica Pharma LLC | $40.53 | 2024-2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $21.61 | 2024 | Secuado, Xelstrym |
| Supernus Pharmaceuticals, INC. | $19.04 | 2021 | |
| Acadia Pharmaceuticals INC | $16.91 | 2024 | Nuplazid |
| Collegium Pharmaceutical, INC. | $15.96 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Debelius-Enemark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.